302 related articles for article (PubMed ID: 33761021)
1. Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result.
Metcalfe KA; Eisen A; Poll A; Candib A; McCready D; Cil T; Wright F; Demsky R; Mancuso T; Sun P; Narod SA
Ann Surg Oncol; 2021 Sep; 28(9):4967-4973. PubMed ID: 33761021
[TBL] [Abstract][Full Text] [Related]
2. Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors.
Graves KD; Peshkin BN; Halbert CH; DeMarco TA; Isaacs C; Schwartz MD
Breast Cancer Res Treat; 2007 Sep; 104(3):321-9. PubMed ID: 17066320
[TBL] [Abstract][Full Text] [Related]
3. Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer.
Hamilton JG; Genoff MC; Salerno M; Amoroso K; Boyar SR; Sheehan M; Fleischut MH; Siegel B; Arnold AG; Salo-Mullen EE; Hay JL; Offit K; Robson ME
Breast Cancer Res Treat; 2017 Apr; 162(2):297-306. PubMed ID: 28150129
[TBL] [Abstract][Full Text] [Related]
4. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers.
van Sprundel TC; Schmidt MK; Rookus MA; Brohet R; van Asperen CJ; Rutgers EJ; Van't Veer LJ; Tollenaar RA
Br J Cancer; 2005 Aug; 93(3):287-92. PubMed ID: 16052221
[TBL] [Abstract][Full Text] [Related]
5. Rapid Genetic Testing for BRCA1 and BRCA2 Mutations at the Time of Breast Cancer Diagnosis: An Observational Study.
Metcalfe KA; Eisen A; Poll A; Candib A; McCready D; Cil T; Wright F; Lerner-Ellis J; McCuaig J; Graham T; Sun P; Akbari M; Narod SA
Ann Surg Oncol; 2021 Apr; 28(4):2219-2226. PubMed ID: 32989658
[TBL] [Abstract][Full Text] [Related]
6. Impact of genetic counseling on the uptake of contralateral prophylactic mastectomy among younger women with breast cancer.
Terkelsen T; Rønning H; Skytte AB
Acta Oncol; 2020 Jan; 59(1):60-65. PubMed ID: 31379231
[No Abstract] [Full Text] [Related]
7. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
8. Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients.
Tynan M; Peshkin BN; Isaacs C; Willey S; Valdimarsdottir HB; Nusbaum R; Hooker G; O'Neill SC; Jandorf L; Kelly SP; Heinzmann J; Kelleher S; Poggi E; Schwartz MD
Breast Cancer Res Treat; 2020 Feb; 180(1):177-185. PubMed ID: 31894446
[TBL] [Abstract][Full Text] [Related]
9. Women's preferences for contralateral prophylactic mastectomy following unilateral breast cancer: What risk-reduction makes it worthwhile?
Tesson S; Richards I; Porter D; Phillips KA; Rankin N; Costa D; Musiello T; Marven M; Butow P
Breast; 2017 Feb; 31():233-240. PubMed ID: 27969575
[TBL] [Abstract][Full Text] [Related]
10. Predictors of uptake of contralateral prophylactic mastectomy in women with nonhereditary breast cancer.
Metcalfe KA; Retrouvey H; Kerrebijn I; Butler K; O'Neill AC; Cil T; Zhong T; Hofer SOP; McCready DR
Cancer; 2019 Nov; 125(22):3966-3973. PubMed ID: 31435939
[TBL] [Abstract][Full Text] [Related]
11. Short report: Follow-up of Bahamian women with a BRCA1 or BRCA2 mutation.
Narod SA; Butler R; Bobrowski D; Akbari MR; Curling D; Lunn J; Ho C; Panahi S; Llacuachaqui M; Donenberg T; Hurley J
Mol Genet Genomic Med; 2018 Mar; 6(2):301-304. PubMed ID: 29266833
[TBL] [Abstract][Full Text] [Related]
12. Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: findings from a randomised controlled trial.
Wevers MR; Aaronson NK; Verhoef S; Bleiker EM; Hahn DE; Kuenen MA; van der Sanden-Melis J; Brouwer T; Hogervorst FB; van der Luijt RB; Valdimarsdottir HB; van Dalen T; Theunissen EB; van Ooijen B; de Roos MA; Borgstein PJ; Vrouenraets BC; Vriens E; Bouma WH; Rijna H; Vente JP; Witkamp AJ; Rutgers EJ; Ausems MG
Br J Cancer; 2014 Feb; 110(4):1081-7. PubMed ID: 24423928
[TBL] [Abstract][Full Text] [Related]
13. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
14. Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing.
Tercyak KP; Peshkin BN; Brogan BM; DeMarco T; Pennanen MF; Willey SC; Magnant CM; Rogers S; Isaacs C; Schwartz MD
J Clin Oncol; 2007 Jan; 25(3):285-91. PubMed ID: 17159191
[TBL] [Abstract][Full Text] [Related]
15. Contralateral prophylactic mastectomy in breast cancer patients who test negative for BRCA mutations.
Howard-McNatt M; Schroll RW; Hurt GJ; Levine EA
Am J Surg; 2011 Sep; 202(3):298-302. PubMed ID: 21871984
[TBL] [Abstract][Full Text] [Related]
16. What made her give up her breasts: a qualitative study on decisional considerations for contralateral prophylactic mastectomy among breast cancer survivors undergoing BRCA1/2 genetic testing.
Kwong A; Chu AT
Asian Pac J Cancer Prev; 2012; 13(5):2241-7. PubMed ID: 22901201
[TBL] [Abstract][Full Text] [Related]
17. International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers.
Semple J; Metcalfe KA; Lynch HT; Kim-Sing C; Senter L; Pal T; Ainsworth P; Lubinski J; Tung N; Eng C; Gilchrist D; Blum J; Neuhausen SL; Singer CF; Ghadirian P; Sun P; Narod SA;
Ann Surg Oncol; 2013 Nov; 20(12):3817-22. PubMed ID: 23740344
[TBL] [Abstract][Full Text] [Related]
18. Timing of genetic testing in BRCA1/2 and PALB2-Associated breast cancer: Preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy.
Apostolova C; Ferroum A; Alhassan B; Prakash I; Basik M; Boileau JF; Martel K; Meterissian S; Villareal Corpuz V; Wong N; Foulkes WD; Wong SM
Eur J Surg Oncol; 2024 Jun; 50(6):108324. PubMed ID: 38636249
[TBL] [Abstract][Full Text] [Related]
19. Survival Outcomes in Women with Unilateral, Triple-Negative, Breast Cancer Correlated with Contralateral Prophylactic Mastectomy.
Fasano GA; Bayard S; Chen Y; Marti J; Simmons R; Swistel A; Bensenhaver J; Davis M; Newman L
Ann Surg Oncol; 2023 Aug; 30(8):4648-4656. PubMed ID: 36681737
[TBL] [Abstract][Full Text] [Related]
20. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
